|Security||HEB / Hemispherx BioPharma, Inc. (42366C103)|
|Exec. Vice Chairman/CEO/Pres.||Equels Thomas K.|
|Industry||Biological Products, Except Diagnostic Substances (Biotech)|
|Institutional Shares||2,058,960 - 4.46%|
|Common Shares Outstanding||46,202,997 shares (as of 2018-03-31)|
|Institutional Value||$ 957,000 USD|
Institutional Stock Ownership and Shareholders()
Hemispherx BioPharma, Inc. (AMEX:HEB) has 26 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,058,960 shares.
Largest shareholders include
BlackRock Institutional Trust Company, N.A., BlackRock Inc., Vanguard Group Inc, Citadel Advisors Llc, Citadel Advisors Llc, Geode Capital Management, Llc, Creative Planning, Virtu Financial LLC, Northern Trust Corp, and Two Sigma Securities, Llc.
Hemispherx BioPharma, Inc. (AMEX:HEB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/heb"><img src="https://images.fintel.io/us-heb-so.png" alt="HEB / Hemispherx BioPharma, Inc. Institutional Ownership"><a>
|Virtu Financial LLC||61,278||34,330||-43.98||21||14||-33.33|
|VANGUARD GROUP INC||294,489||451,169||53.20||102||178||74.51|
|WELLS FARGO & COMPANY/MN||20,000||0||-100.00||7||0||-100.00|
|GUGGENHEIM CAPITAL LLC||19,495||19,614||0.61||7||8||14.29|
|Well Done, LLC||190||0|
|BlackRock Fund Advisors||5,284||6,904||30.66||7||5||-28.57|
|NORTHERN TRUST CORP||31,933||31,933||0.00||11||13||18.18|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||53,335||0||-100.00||18||0||-100.00|
|ROYAL BANK OF CANADA||237||21||-91.14||0||0|
|CITY HOLDING CO||417||417||0.00||0||0|
|DEUTSCHE BANK AG\||24||24||0.00||0||0|
|UBS Group AG||6,102||1,714||-71.91||3||1||-66.67|
|Jacobi Capital Management LLC||318||318||0.00||0||0|
|CITADEL ADVISORS LLC||200,749||79|
|GEODE CAPITAL MANAGEMENT, LLC||74,832||74,832||0.00||25||29||16.00|
|LADENBURG THALMANN FINANCIAL SERVICES INC||80||1,080||1,250.00||0||0|
|Bank of New York Mellon Corp||12,464||10,699||-14.16||5||4||-20.00|
|TWO SIGMA SECURITIES, LLC||79,881||28,853||-63.88||28||11||-60.71|
|BlackRock Advisors LLC||5,727||5,727||0.00||7||4||-42.86|
|BANK OF MONTREAL /CAN/||209||209||0.00||0||0|
|CITADEL ADVISORS LLC||47,096||200,749||326.25||16||79||393.75|
|Sound Income Strategies, Llc||9||9||0.00||0||0|
|Renaissance Technologies LLC||26,052||0||-100.00||9||0||-100.00|
|BlackRock Institutional Trust Company, N.A.||479,699||479,701||0.00||604||331||-45.20|
|Advisor Group, Inc.||250||250||0.00||0||0|
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Related News Stories
Eleven Biotherapeutics is continuing its highly robust trading momentum. There is a good chance that the upcoming clinical outcome for Vicinium monotherapy is positive. (77-3)
as of ET